Press Releases Year None202120202019201820172016 May 11, 2021 Imara Reports First Quarter 2021 Financial Results and Business Highlights May 04, 2021 Imara to Webcast Conference Call of First Quarter 2021 Financial Results and Business Highlights Mar 29, 2021 Imara Opens Applications for the Second-Annual ‘Real Impact’ Community Support Program to Address Unmet Needs Affecting People with Rare Genetic Blood Disorders Mar 17, 2021 Imara Announces Opening of Higher Dose Arms in Global Phase 2b Clinical Trials of IMR-687 for Sickle Cell Disease and Beta-Thalassemia Mar 05, 2021 Imara Reports Full Year 2020 Financial Results and Business Highlights Feb 26, 2021 Imara to Webcast Conference Call of Full Year 2020 Financial Results and Business Highlights Feb 19, 2021 Imara to Present at SVB Leerink 10th Annual Global Healthcare Conference Jan 20, 2021 Imara Announces the Appointment of Kenneth Attie, M.D. as Chief Medical Officer Jan 06, 2021 Imara Reports Phase 2a Clinical Trial Results of IMR-687 in Adult Patients with Sickle Cell Disease
Press Releases Year None202120202019201820172016 May 11, 2021 Imara Reports First Quarter 2021 Financial Results and Business Highlights May 04, 2021 Imara to Webcast Conference Call of First Quarter 2021 Financial Results and Business Highlights Mar 29, 2021 Imara Opens Applications for the Second-Annual ‘Real Impact’ Community Support Program to Address Unmet Needs Affecting People with Rare Genetic Blood Disorders Mar 17, 2021 Imara Announces Opening of Higher Dose Arms in Global Phase 2b Clinical Trials of IMR-687 for Sickle Cell Disease and Beta-Thalassemia Mar 05, 2021 Imara Reports Full Year 2020 Financial Results and Business Highlights Feb 26, 2021 Imara to Webcast Conference Call of Full Year 2020 Financial Results and Business Highlights Feb 19, 2021 Imara to Present at SVB Leerink 10th Annual Global Healthcare Conference Jan 20, 2021 Imara Announces the Appointment of Kenneth Attie, M.D. as Chief Medical Officer Jan 06, 2021 Imara Reports Phase 2a Clinical Trial Results of IMR-687 in Adult Patients with Sickle Cell Disease
May 04, 2021 Imara to Webcast Conference Call of First Quarter 2021 Financial Results and Business Highlights
Mar 29, 2021 Imara Opens Applications for the Second-Annual ‘Real Impact’ Community Support Program to Address Unmet Needs Affecting People with Rare Genetic Blood Disorders
Mar 17, 2021 Imara Announces Opening of Higher Dose Arms in Global Phase 2b Clinical Trials of IMR-687 for Sickle Cell Disease and Beta-Thalassemia
Feb 26, 2021 Imara to Webcast Conference Call of Full Year 2020 Financial Results and Business Highlights
Jan 06, 2021 Imara Reports Phase 2a Clinical Trial Results of IMR-687 in Adult Patients with Sickle Cell Disease
